Free Submission Public Relations & NewsPR-inside.com
Home
Deutsch English

Business

Free Research Reports on CAT, HNSN, IPXL and KERX Issued by the Bedford Report Note to Editors: The Following Is an Investment Opinion Being Issued by the EQUITY NEWS CIRCUIT


Print article Print article
© Marketwire 2013
2013-01-23 14:47:56 -

NEW YORK, NY -- (Marketwire) -- 01/23/13 -- The Bedford Report has released new equity reports today. As a leading provider of free in depth reports and timely market updates, Bedford is an essential resource for hundreds of thousands of investors across the country.



Caterpillar Inc. (NYSE: CAT) shares fell sharply in early trading Thursday after reporting it had found major accounting errors at the recently acquired ERA Mining Machinery Limited. This deliberate misconduct at Siwei will result in a non-cash goodwill impairment charge of approximately $580 million, or $0.87 per share, in the fourth quarter of 2012.





Find out more about Caterpillar including full access to the free equity report at: www.BedfordReport.com/CAT : www.bedfordreport.com/CAT



Hansen Medical, Inc. (NASDAQ: HNSN) is the global leader in intravascular robotics. Shares of the company spiked 14 percent on more than five-times the average daily volume Tuesday. The company has recently named Robert Cathcart as the company's Senior Vice President of Global Sales.



Find out more about Hansen Medical including full access to the free equity report at: www.BedfordReport.com/HNSN : www.bedfordreport.com/HNSN



Impax Laboratories Inc. (NASDAQ: IPXL) shares declined 7 percent on nearly 4 million shares traded Tuesday. The company has recently received a complete response letter regarding the New Drug Application for RYTARY from the FDA requesting a satisfactory re-inspection of the company's Hayward facility.



Find out more about Impax Laboratories including full access to the free equity report at: www.BedfordReport.com/IPXL : www.bedfordreport.com/IPXL



Keryx Biopharmaceuticals (NASDAQ: KERX) shares soared 18 percent on nearly three-times the average daily volume Tuesday. The company earlier this month reported that it has filed a New Drug Application for marketing approval of ferric citrate in Japan.



Find out more about Keryx Biopharmaceuticals including full access to the free equity report at: www.BedfordReport.com/KERX : www.bedfordreport.com/KERX



Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein.



A third party, Providence Media Strategies LLC has paid Equity News Circuit four hundred and fifty dollars for the publication of this news release. Neither Equity News Circuit, nor the hiring party, has a financial relationship with any company whose stock is mentioned in this release. Neither Equity News Circuit nor the hiring party are a registered investment advisor, and nothing in this report is intended as a solicitation to buy or sell any security.




Contact Information:

Equity News Circuit
Email Contact : www2.marketwire.com/mw/emailprcntct?id=075DFC296F440D68



Press Information:




Contact Person:


Disclaimer: (c) 2014 Market Wire. All of the press releases contained herein are protected by copyright and other applicable laws, treaties and conventions. Information contained in the releases is furnished by Market Wire's, who warrant that they are solely responsible for the content, accuracy and originality of the information contained therein. All reproduction, other than for an individual user's personal reference, is prohibited without prior written permission.
Latest News
Read the Latest News
www.newsenvoy.com

 


Terms & Conditions | Privacy | About us | Contact PR-inside.com